Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.57B 11B 10.14B 9.4B 17.84B 1,193B 18.13B 122B 47.29B 589B 47.21B 46.18B 2,036B P/E 2026 *
-78.2x
P/E 2027 * 55.2x
Enterprise Value 12.04B 10.54B 9.71B 9B 17.09B 1,143B 17.37B 116B 45.3B 564B 45.22B 44.24B 1,950B EV / Sales 2026 *
8.05x
EV / Sales 2027 * 5.2x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+3.00%
1 week+1.57%
Current month+1.57%
1 month+11.99%
3 months+6.54%
6 months-2.81%
Current year-6.35%
1 week 507.6
Extreme 507.6
554
1 month 460.89
Extreme 460.89
554
Current year 416.21
Extreme 416.21
598.79
1 year 286.44
Extreme 286.44
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 07/09/2023
Director of Finance/CFO 62 10/03/2024
Chief Tech/Sci/R&D Officer 58 20/04/2025
Director TitleAgeSince
Director/Board Member 74 30/06/2016
Director/Board Member 68 10/08/2016
Director/Board Member 64 26/06/2019
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Founder

1,220 0.0053%
06-16Free

Director

1,085 0.0047%
06-16Free

Director

1,220 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
+3.00%+1.57%+88.59%+148.88% 12.57B
-1.01%+1.31%+73.24%+128.67% 57.72B
-3.80%-6.24%+67.04%+86.36% 52.65B
+1.17%+5.83%+16.39%+468.18% 24.46B
+0.38%+1.33%-14.32%-11.76% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.15%+5.43%+44.69%-26.39% 17.8B
+3.46%+17.72%+206.66%+364.07% 17.29B
-6.73%+9.90%+36.04% - 15.28B
+2.79%+4.91%+29.26%+195.60% 14.35B
Average -0.40%+4.80%+58.99%+149.77% 25.52B
Weighted average by Cap. -0.97%+2.53%+59.10%+139.76%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.21B 1.12B 2.12B 142B 2.16B 14.46B 5.62B 70.05B 5.61B 5.49B 242B 2.21B 1.93B 1.78B 1.65B 3.13B 209B 3.18B 21.33B 8.3B 103B 8.28B 8.1B 357B
Net income -201M -176M -162M -150M -285M -19.08B -290M -1.94B -756M -9.41B -755M -738M -32.54B 308M 269M 248M 230M 437M 29.2B 444M 2.98B 1.16B 14.41B 1.16B 1.13B 49.81B
Net Debt -529M -463M -427M -396M -751M -50.23B -763M -5.12B -1.99B -24.79B -1.99B -1.94B -85.68B -1.09B -958M -883M -818M -1.55B -104B -1.58B -10.59B -4.12B -51.27B -4.11B -4.02B -177B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
07/07/26 US$545.36 +3.00% 318,420
06/07/26 US$529.48 +0.26% 230,982
02/07/26 US$528.10 +2.67% 221,894
01/07/26 US$514.39 -4.20% 303,751
30/06/26 US$536.95 +1.83% 393,459
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
545.36USD
Average target price
678.71USD
Spread / Average Target
+24.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock